
    
      A first cohort of three patients will be treated at the starting dose level of Vorinostat 100
      mg/d, on day 1-4, 8-11, and 15-18 in combination with BDD.

      The dose level of Vorinostat will be escalated in each new cohort:

      if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient,
      the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d and the third
      cohort will be given Vorinostat with 300 mg/d.

      Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 d1, 8, 15. Doxorubicin will be
      administered i.v. with a total dose of 18 mg/m2 per cycle (9 mg/m2, d1 and 8).

      Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) and 20mg (all other
      subsequent cycles) on d1, 8, 15, 22.
    
  